Resource Summary Report

Generated by dkNET on Aug 16, 2026

Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA)

RRID:AB_2629749
Type: Antibody

Proper Citation

BioLegend Cat# 138429, RRID:AB_2629749

Antibody Information

URL: http://antibodyregistry.org/AB_2629749

Proper Citation: BioLegend Cat# 138429, RRID:AB_2629749

Target Antigen: KLRG1

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA)

Description: This monoclonal targets KLRG1

Target Organism: mouse, human

Clone ID: Clone 2F1/KLRG1

Antibody ID: AB_2629749

Vendor: BioLegend

Catalog Number: 138429

Record Creation Time: 20250820T042117+0000

Record Last Update: 20250820T184440+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA).

No alerts have been found for Brilliant Violet 785(TM) anti-mouse/human KLRG1 (MAFA).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Grassmann S, et al. (2026) Stepwise epigenetic signal integration drives adaptive programming of cytotoxic lymphocytes. Immunity, 59(2), 339.

Cortez VS, et al. (2025) IL-25-induced memory type 2 innate lymphoid cells enforce mucosal immunity. Cell.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. Immunity, 58(7), 1742.

Mujal AM, et al. (2025) Splenic TNF-? signaling potentiates the innate-to-adaptive transition of antiviral NK cells. Immunity, 58(3), 585.

Harris RJ, et al. (2025) OMIP-119: A 36-Color Full-Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Peripheral Blood and Ex Vivo Expanded Human T Cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology, 107(12), 787.

Corgnac S, et al. (2025) TGF-? and IL-12 conversely orchestrate the formation of CD103+ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine. iScience, 28(8), 113147.

Cortez VS, et al. (2025) IL-25-induced memory ILC2s mediate long-term small intestinal adaptation. bioRxiv : the preprint server for biology.

Linger ME, et al. (2025) Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice. iScience, 28(10), 113479.

Fang X, et al. (2025) The m6A reader HNRNPC is a key regulator in DSS-induced colitis by modulating macrophage phenotype. iScience, 28(3), 111812.

Das A, et al. (2024) Transcription factor Tox2 is required for metabolic adaptation and tissue residency of ILC3 in the gut. Immunity, 57(5), 1019.

Chen DG, et al. (2024) Integrative systems biology reveals NKG2A-biased immune responses correlate with protection in infectious disease, autoimmune disease, and cancer. Cell reports, 43(3), 113872.

López DA, et al. (2024) Prenatal inflammation remodels lung immunity and function by programming ILC2 hyperactivation. Cell reports, 43(7), 114365.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity, 56(1), 207.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.

Krämer B, et al. (2023) Single-cell RNA sequencing identifies a population of human liver-type ILC1s. Cell reports, 42(1), 111937.

Dutt TS, et al. (2022) Mucosal exposure to non-tuberculous mycobacteria elicits B cell-mediated immunity against pulmonary tuberculosis. Cell reports, 41(11), 111783.

Hanna BS, et al. (2021) Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Immunity, 54(12), 2825.

Dammeijer F, et al. (2020) The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes. Cancer cell, 38(5), 685.